Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Dingkong Liang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-4628-3556; OpenAlex author ID A5112216055. Sources: OpenAlex.

Their work

Papers
21
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2015: 1 paper · 2016: 6 papers · 2017: 7 papers · 2018: 6 papers · 2019: 1 paper

Papers 21

  1. Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002668↗
  2. MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. Co-author DOI 10.1002/ijc.31654↗
  3. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Co-author DOI 10.1007/s00018-017-2678-7↗
  4. Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.surg.2017.12.009↗
  5. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling. Co-author DOI 10.1038/s41388-018-0392-z↗
  6. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. Co-author DOI 10.1038/s41419-018-0367-6↗
  7. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Co-author DOI 10.2147/ott.s166405↗
  8. ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.12.014↗
  9. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Co-author DOI 10.1038/emm.2017.255↗
  10. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-16-0296↗
  11. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.2147/ott.s145708↗
  12. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗
  13. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Co-author DOI 10.3892/or.2017.5856↗
  14. Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.7150/jca.18901↗
  15. New insights into perineural invasion of pancreatic cancer: More than pain. Co-author DOI 10.1016/j.bbcan.2016.01.002↗
  16. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbcan.2016.09.001↗
  17. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.054↗
  18. Energy sources identify metabolic phenotypes in pancreatic cancer. Co-author DOI 10.1093/abbs/gmw097↗
  19. FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancr… Co-author DOI 10.1158/1078-0432.ccr-15-2380↗
  20. Critical role of oncogenic KRAS in pancreatic cancer (Review). Co-author DOI 10.3892/mmr.2016.5196↗
  21. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Co-author DOI 10.1038/cr.2015.30↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Xu · 21 shared papers, 2015–2019 · strength 1.35
  2. Xianjun Yu · 21 shared papers, 2015–2019 · strength 1.35
  3. Si Shi · 21 shared papers, 2015–2019 · strength 1.35
  4. Quanxing Ni · 20 shared papers, 2015–2019 · strength 1.26
  5. Chen Liang · 19 shared papers, 2016–2019 · strength 1.26
  6. Yi Qin · 16 shared papers, 2015–2018 · strength 0.93
  7. Shunrong Ji · 16 shared papers, 2015–2018 · strength 0.92
  8. Qingcai Meng · 11 shared papers, 2017–2019 · strength 0.83
  9. Wenyan Xu · 14 shared papers, 2015–2018 · strength 0.77
  10. Jinfeng Xiang · 8 shared papers, 2016–2018 · strength 0.47
  11. Qiangsheng Hu · 7 shared papers, 2016–2018 · strength 0.41
  12. Jie Hua · 4 shared papers, 2018–2019 · strength 0.35
  13. Liang Liu · 7 shared papers, 2015–2017 · strength 0.34
  14. Chen Liu · 6 shared papers, 2015–2017 · strength 0.29
  15. Kaizhou Jin · 3 shared papers, 2016 · strength 0.14
  16. Jiang Long · 3 shared papers, 2015–2017 · strength 0.14
  17. Bo Zhang · 2 shared papers, 2017 · strength 0.12
  18. Wensheng Liu · 2 shared papers, 2017–2018 · strength 0.12
  19. Paul J. Chiao · 2 shared papers, 2015–2016 · strength 0.09
  20. Bo Zhang · 1 shared paper, 2018 · strength 0.07
  21. Pengfei Hu · 1 shared paper, 2017 · strength 0.05
  22. Jiang Liu · 1 shared paper, 2016 · strength 0.05
  23. Guopei Luo · 1 shared paper, 2016 · strength 0.05
  24. Huaxiang Xu · 1 shared paper, 2016 · strength 0.05
  25. Wenquan Wang · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.